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A B S T R A C T
Sulfatide is a major glycosphingolipid in myelin and a target for autoantibodies in autoimmune neuropathies.
However neuropathy disease models have not been widely established, in part because currently available
monoclonal antibodies to sulfatide may not represent the diversity of anti-sulfatide antibody binding patterns
found in neuropathy patients. We sought to address this issue by generating and characterising a panel of new
anti-sulfatide monoclonal antibodies. These antibodies have sulfatide reactivity distinct from existing antibodies
in assays and in binding to peripheral nerve tissues and can be used to provide insights into the pathophysio-
logical roles of anti-sulfatide antibodies in demyelinating neuropathies.
1. Introduction
Sulfoglycolipids are common components of the mammalian plasma
membrane that are distinguished by the presence of a sulfate group.
Among the more abundant sulfoglycolipids is sulfatide, 3-O sulfoga-
lactosylceramide, formed from galactocerebroside through the enzy-
matic action of cerebroside sulfotransferase (CST)(Honke et al., 2002).
Sulfatide is expressed at low levels in many tissues but is particularly
enriched in the myelin sheaths of the central and peripheral nervous
systems (Takahashi and Suzuki, 2012).
In the nervous system sulfatide modulates diverse functions in-
cluding myelin maintenance and stabilisation (Hirahara et al., 2004;
Palavicini et al., 2016). Its importance in myelin homeostasis is evi-
denced in sulfatide-deﬁcient mice lacking cerebroside sulfotransferase
(CST−/−) which develop normally up to six weeks, thereafter dis-
playing progressive hindlimb paralysis, tremor and ataxia (Honke et al.,
2002). Morphologically, myelinated nerves from CST−/− mice initially
form compact myelin and exhibit normal axons and ion channel clus-
tering at the nodes of Ranvier. After 6 weeks, disorganisation of the
myelin and disassembly of the nodes of Ranvier and paranodal junc-
tions occurs, indicated by decreased Na+ and K+ channel clustering
and abnormal distribution of K+ channels that are misplaced from the
juxtaparanodes into the paranode (Hoshi et al., 2007; Ishibashi et al.,
2002; Marcus et al., 2006; Takano et al., 2012). These disturbances
directly correlate with sulfatide content in the peripheral nerve, as
evidenced by combined biochemical and functional studies (Hayashi
et al., 2013). However, the temporal and mechanistic sequence by
which these demyelinating events evolve is not understood, in part
owing to limited information on sulfatide distribution in glial cell
membranes.
In addition to its essential role in myelin homeostasis, sulfatide has
also long been considered as a possible autoantigen in disease in which
antibody targeting of the glycolipid in myelin would be expected to
have detrimental eﬀect on nerve function. Antibodies that bind sulfa-
tide are widespread in both normal and disease populations but they
are particularly prevalent in patients with multiple sclerosis (MS),
Guillain-Barré syndrome (GBS) and paraproteinaemia-associated neu-
ropathy (Nobile-Orazio et al., 2014; Nobile-Orazio et al., 1994; van den
Berg et al., 1993). In MS, anti-sulfatide antibodies have been found in
cerebrospinal ﬂuid, suggesting local intrathecal synthesis by ectopic B
cells (Brennan et al., 2011; Ilyas et al., 2003; Kanter et al., 2006). In
cohorts of GBS and other autoimmune neuropathy cases, serum anti-
sulfatide antibodies have been reported with varying sensitivity and
speciﬁcity (Fredman et al., 1991; Halstead et al., 2016; Ilyas et al.,
1991; Morikawa et al., 2016; Petratos et al., 1999; Rinaldi et al., 2013;
Terryberry et al., 1995). Antibodies binding to sulfatide have been
predominantly linked with demyelinating neuropathies, consistent with
the abundance of the glycolipid in myelin, but have also been asso-
ciated with neuropathies characterised by prominent axonal loss (Carpo
et al., 2000). Overall, evidence indirectly indicates that anti-sulfatide
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antibodies are associated with a proportion of autoimmune neuropathy
cases and may play a role in pathogenesis; however experimental evi-
dence on causality is lacking and their use as a diagnostic or prognostic
factor is still uncertain (Giannotta et al., 2015).
Attempts to study and model demyelinating neuropathies have
primarily been carried out using monoclonal antibodies. The most
widely used anti-sulfatide monoclonal antibody is the IgM antibody
termed O4 (Sommer and Schachner, 1981), despite the generation and
characterisation of other antibodies (Cheng et al., 2005; Colsch et al.,
2008; Fredman et al., 1988; Hofstetter et al., 1984). Using O4, the
demyelinating and dysmyelinating eﬀects of anti-sulfatide antibodies in
vitro and in vivo have been studied in the CNS (Elliott et al., 2012;
Kanter et al., 2006; Rosenbluth and Moon, 2003; Rosenbluth et al.,
2003); however, similar studies examining the eﬀects of anti-sulfatide
antibodies in the PNS have been very limited. One experimental model
of peripheral nerve demyelination has been induced through sulfatide
immunisation, resulting in neuropathy accompanied by IgG anti-sulfa-
tide antibodies (Qin and Guan, 1997). As antibodies of the IgG isotype
can opsonise tissue, they are capable of eliciting a pathogenic response
through activation of complement. Complement deposits have been
observed in human nerve biopsies from patients with circulating anti-
lipid antibodies, and complement-mediated injury is a recognised me-
chanism of pathology in demyelinating diseases (Ferrari et al., 1998;
Hafer-Macko et al., 1996; Storch and Lassmann, 1997).
Autoimmune neuropathy models within our own laboratory using
O4 have had limited success, in part due to diﬃculty in clearly de-
monstrating binding of the O4 antibody in live peripheral nerve and
nerve-muscle preparations by immunohistology. A previous study
showed that human recombinant anti-sulfatide antibodies derived from
the cerebrospinal ﬂuid of MS patients were unable to bind live CNS
myelin or cells from the oligodendrocyte lineage despite binding sul-
fatide in solid phase assays (Brennan et al., 2011). It has thus been
hypothesised that there are diﬀerences in the abilities of antibodies to
bind sulfatide in neural plasma membranes, most likely due to steric
hindrance in the plane of the plasma membrane preventing antibody
access, as previously described for anti-ganglioside antibodies
(Greenshields et al., 2009). Furthermore, it is equally possible that the
topographical organisation of sulfatide may diﬀer between CNS and
PNS. Therefore, to aid in development of models of peripheral de-
myelination, we isolated a more diverse range of anti-sulfatide anti-
bodies than currently available. Herein, we describe the generation and
initial characterisation of the nerve binding properties of a set of IgM
and IgG anti-sulfatide monoclonal antibodies for use in investigating
pathogenic roles of anti-sulfatide antibodies in models of autoimmune
demyelinating neuropathy.
2. Methods
2.1. Animals
DBA mice were supplied by Charles River, Elpinstone, UK. Mice
lacking a functional CST gene (CST−/−) and wild type homozygous
(CST+/+) mice were generated and genotyped as previously described
(Honke et al., 2002); the colony was obtained from Karsten Buschard,
Bartholin Institute, Copenhagen, Denmark. All mice were housed under
controlled conditions consisting of 12 h light/dark cycles in tempera-
ture controlled rooms with food and water provided ad libitum. All
procedures were conducted in accordance with the United Kingdom
Animals (Scientiﬁc Procedures) Act of 1986.
2.2. Active immunisations
Liposomes were generated as described previously (Bowes et al.,
2002). They consisted of 100 μg of sulfatide or 500 μg whole lipid ex-
tract (WLE) derived from homogenised cauda equina with cholesterol
(chol), sphingomyelin (SM) and dicetyl phosphate (DCP) in a 1:5:4:1 M
ratio. Mice were initially injected intraperitoneally (IP) with 100 μl of
0.6 mg/ml ovalbumin in 2% aluminium hydroxide on Day 0. They then
received further IP injections of 100 μl of liposomes on Day 7, 14 and
21. These were followed by 50 μl intravenous injections of liposomes at
200 μg/ml on days 25, 26 and 27. Blood samples (100 μl) were collected
once a week via tail venesection, clotted at room temperature for
30min then centrifuged at 21,000 ×g for 20min at 4 °C.
2.3. Hybridoma production
All mice were culled on day 28 post immunisation with a rising
concentration of CO2 as per UK Home Oﬃce guidelines. Spleens were
fused with the myeloma cell line P3X63Ag8.653 to create hybridomas,
as described previously with minor modiﬁcations (Goodyear et al.,
1999). Brieﬂy, feeder cells were replaced with hybridoma supplements,
either 10% Opticlone (Santa Ana, CA, USA) or 5% HyMax (Antibody
Research Corporation, St Charles, MO, USA). Hydridoma supernatants
were screened using a lipid microarray instead of ELISA, as described in
Section 2.4. This allowed for the simultaneous detection of diﬀerent
antibody isotypes. IgM supernatant was concentrated using the Vivacell
250 (Sartorius, Göttingen, Germany) and quantiﬁed using an ELISA kit
(Bethyl Laboratories, Montgomery, TX, USA). IgG antibodies were
puriﬁed using HiTrap protein G aﬃnity puriﬁcation columns (GE
Healthcare, Little Chalfont, UK). These antibodies were quantiﬁed using
both a Nanodrop 1000 spectrophotometer (ThermoScientiﬁc, Waltham,
MA, USA) at a wavelength of 280 nm and a BCA protein assay (Ther-
moScientiﬁc, Waltham, MA, USA). IgG subclasses were determined by
ELISA using speciﬁc anti-mouse antibodies as described previously
(Willison and Veitch, 1994). O4 monoclonal antibody, derived from
hybridoma supernatant, was kindly gifted by Prof Susan Barnett at the
University of Glasgow.
2.4. Glycolipid antibody screening by microarray
Serum samples, hybridoma supernatants and puriﬁed antibodies
were screened against single glycolipids and glycolipid complexes
printed using a glycolipid microarray (Halstead et al., 2016). This is a
miniaturised version of the combinatorial glycoarray described pre-
viously (Rinaldi et al., 2009). Brieﬂy, stock solutions of glycolipids in-
cluding GM1, GM3, GD1a, GD1b, GT1a, GQ1b, GD3, SGPG, and LM1
were prepared in methanol at 0.4mg/ml. Glycolipid complexes were
prepared by adding an equivalent quantity of each working solution in
1:1 (mol:mol or weight:weight) ratios. For hybridoma screening stu-
dies, cholesterol (chol) was made up at a molar weight ﬁve times that of
all other glycolipids. A microarray printer (sciFLEXARRAYER S3, Sci-
enion, Berlin, Germany) was used to print glycolipid spots in a pre-
deﬁned pattern onto low ﬂuorescence PVDF membrane-covered slides
(Millipore, Billerica, MA, USA). Slides were then blocked with 2% BSA/
PBS at room temperature for 1 h. Serum samples (100 μl, 1:50 dilution
in 1% BSA/PBS), puriﬁed anti-sulfatide antibody (10 μg/ml of IgM or
1 μg/ml of IgG) or neat hybridoma supernatants were applied to the
slides for 1 h at 4 °C, then washed twice for 15min in 1% BSA/PBS.
AlexaFluor 555 or AlexaFluor 647 conjugated mouse IgM or IgG heavy
chain speciﬁc antibodies (Jackson ImmunoResearch laboratories, inc,
West Grove, PA, USA) were applied to the slides at 2 μg/ml in 1% BSA/
PBS for 1 h at 4 °C. Slides were washed 2×30min in 1% BSA/PBS,
2×5min in PBS then ﬁnally 5min in dH2O. Slides were imaged using
either a Sensovation FLAIR scanner (Sensovation, Radolfzell, Germany)
or a GenePix 4300A scanner (Molecular Devices, Sunnyvale, USA).
Antibody binding was quantiﬁed using the accompanying software with
values expressed as median ﬂuorescent intensity (MFI).
2.5. Cell culture
Mouse central nervous system (CNS) myelinating cultures were
grown on poly-L-lysine coated coverslips as per established methods
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(Thomson et al., 2008).
2.6. Antibody localisation
2.6.1. Myelinating cell cultures
At 28 days in vitro (DIV), cell cultures were incubated with anti-
sulfatide antibody (10 μg/ml) for 1.5 h at room temperature, rinsed in
PBS, ﬁxed with 4% paraformaldehyde (PFA) and permeabilised in
−20 °C ethanol for 10 mins. Anti-myelin basic protein (MBP) antibody
(#aa82-87 BioRad, 1:500) was applied overnight at 4 °C. After washing
in PBS, goat anti-rat Alexaﬂuor 488 and an IgG or IgM goat anti-mouse
555 (Invitrogen, Paisley) secondary antibody was then applied for
30min at room temperature. The cells were washed again and mounted
in Citiﬂuor antifade containing DAPI (Electron Microscopy Sciences
Pennsylvania US).
2.6.2. Tissue
Phrenic nerve-diaphragm nerve-muscle preparations were dissected
from 6 to 10 week old CST+/+ and CST−/− mice, snap frozen, and
sectioned transversely at 10 μm. Sections were blocked in 3% NGS in
PBS for 1 h at 4 °C, followed by application of the anti-sulfatide anti-
bodies at 10 μg/ml and 1/1500 mouse anti-phosphorylated neuroﬁla-
ment-H antibody (NF-H, #801602 clone SMI31, BioLegend 1:2000) O/
N at 4 °C. Slides were washed with PBS followed by incubation with
FITC-conjugated goat anti-mouse IgG3 (Fcγ) or IgM (μ) (Southern
Biotech, Birmingham, AL, USA) and TRITC-conjugated anti-mouse IgG1
(Fcγ) at 3.33 μg/ml for 1 h at 4 °C in PBS. The slides were washed in PBS
and mounted in Citiﬂuor AF1 (Citiﬂuor, Leicester, UK). Whole-mount
triangularis sterni (TS) nerve muscle preparations were used for label-
ling of intact distal myelinated motor nerve bundles. The TS muscle was
removed and maintained alive in an oxygenated Ringer's solution
(116mM NaCl, 4.5 mM KCl, 1 mM MgCl2, 2mM CaCl2, 1mM
NaH2PO4, 23mM NaHCO3, 11mM glucose, pH 7.4). TS was treated
with 100 μg/ml of either anti-sulfatide IgG3 antibody (GAME-G3) or
anti-sulfatide IgM antibody (O4) for 4 h at 32 °C. Control tissue was
treated with PBS only. TS were then washed with Ringer's solution and
ﬁxed in 4% PFA for 20min followed by 10min in 0.1M glycine to
quench unreactive aldehyde groups. Tissue was incubated with 100%
EtOH for 10min at −20 °C, thoroughly washed in PBS and incubated
overnight at 4 °C with 1:1500 anti-neuroﬁlament antibody (SMI-31) in
0.3% Triton X-100+3% NGS. The TS was washed in PBS and in-
cubated with α-bungarotoxin (BTx; 2 μg/ml; Molecular probes), anti-
mouse IgG3/M and anti-mouse IgG1 Alexa Fluor conjugated antibodies
(2 μg/ml; Molecular Probes) for 3 h at room temperature. Tissue was
rinsed in PBS and mounted in Citiﬂuor.
2.6.3. In vivo studies
GAME-G3 antibody (1mg) was administered to CST+/+ and CST−/
− mice by IP injection. Mice were sacriﬁced 20 h later. Diaphragm
tissue was immediately removed and snap-frozen. TS was removed for
preparation in Ringer's, as above. Lumbrical muscles, sciatic nerve and
spinal roots were removed following perfusion with 4% PFA. Whole-
mount TS (30min), lumbricals (1 h), roots (1 h) and sciatic nerve (1 h)
were post-ﬁxed at 4 °C. Tissue was stained as above for TS, but omitting
the primary anti-sulfatide antibody step and in some cases replacing
SMI31 antibody with rat anti-MBP antibody.
2.7. Complement activation
Complement activation was performed using a modiﬁed whole
mount staining protocol. Brieﬂy, TS were treated with 100 μg/ml anti-
sulfatide IgG3 antibody (GAME-G3) for 4 h at 32 °C with a source of
complement (normal human serum, NHS, 40% in Ringer's). Control
tissue was exposed to antibody solution alone. TS were ﬁxed and
stained as before with the inclusion of 1 μg/ml mouse anti-human C5b-
9 (MAC) antibody (1/50, Dako, Santa Clara, CA, USA) overnight. Tissue
was washed in PBS and incubated in isotype-speciﬁc Alexa Fluor 488-,
555- and 647- conjugated antibodies (2 μg/ml; Molecular Probes) for
3 h at room temperature. Tissue was rinsed in PBS and mounted in
Citiﬂuor.
2.8. Antibody internalisation
Baseline blood samples (day−1) were taken from mice via tail vein
venesection one day prior to an IP injection of 250 μg of GAME-G3 (day
0). Further blood samples were taken on days 1, 3 and 6 and a terminal
sample was taken on day 7. These were processed as per Section 2.2.
The serum was screened for anti-sulfatide antibodies by ELISA using the
previously described method (Cunningham et al., 2016).
2.9. Statistical analysis
All graphs and statistical analyses were produced using GraphPad
Prism 6 (GraphPad Software Inc., San Diego, CA, USA). P values <
0.05 were deemed to be signiﬁcant.
2.10. Microscopy
Representative images were taken using an epiﬂuorescent Axio
Imager Z1 microscope with ApoTome attachment (Carl Zeiss,
Oberkochen, Germany).
3. Results
3.1. Anti-sulfatide antibody serum response in diﬀerent mouse strains
CST+/+, CST−/− and DBA mice responded similarly to immunisa-
tions with sulfatide containing liposomes. In order to fully delineate
antibody binding to sulfatide in the presence and context of accessory
binding lipids, sera and monoclonal antibodies were screened using a
combinatorial glycoarrray approach. Combinatorial glycoarrays from
serum taken at day 28 post immunisation indicated that IgM antibodies
were generated to all membrane lipids comprised in the liposomes
(sulfatide, sphingomyelin, cholesterol and DCP) and their complexes;
ﬂuorescence intensity represents the binding signals (Fig. 1A). Anti-
bodies to galactocerebroside were not produced. All genotypes and
strains studied generated anti-sulfatide IgM antibodies, which could be
detected in their sera from 14 days post-immunisation (Fig. 1B). DBA
mice showed a rise in anti-sulfatide IgM antibody response with each
subsequent immunisation and on day 21 the antibody level in these
mice was signiﬁcantly greater than the other genotypes (two-way
ANOVA, P < 0.05). All genotypes reached a peak serum response at
day 28, which showed no signiﬁcant diﬀerence among groups.
In the glycoarray assay, sera showed a weak IgG response to SM,
cholesterol and associated complexes at day 28 in CST−/− and CST+/+
mice, but no anti-sulfatide IgG antibody response was detected in the
serum of either genotype at any time-point (Fig. 1C). In contrast, low
levels of anti-sulfatide IgG antibodies were detectable in DBA mice by
day 28 (Fig. 1D).
Spleens were harvested from the mice that produced the strongest
IgM antibody responses and fused with a myeloma cell line to create
hybridomas. Despite the serological data indicating otherwise for
CST−/− and CST+/+ mice, both anti-sulfatide IgM and IgG antibodies
were detected in the supernatant from these hybridomas when screened
by glycoarray. The cell lines were expanded and cloned repeatedly to
isolate ﬁve anti-sulfatide monoclonal antibodies, four of the IgM class
(GAME-M2, GAME-M5, GAME-M6, GAME-M7) and one IgG class
(GAME-G3, IgG3 subclass), conﬁrmed by screening for sulfatide re-
activity (Table 1).
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3.2. Monoclonal anti-sulfatide antibodies bind to sulfatide and sulfatide-
associated complexes
The binding intensities of the antibodies to various lipid antigens
were determined by lipid microarray. All ﬁve antibodies bound strongly
to sulfatide (Table 1). Binding was not detected to any of the following
single lipid antigens that were screened: GM1, GM3, GD1a, GD1b,
GT1a, GQ1b, GD3, cholesterol, DCP, SM, DPPC, PC, SGPG, and LM1
(data not shown).
In addition to determining the ability of the antibodies to bind
single lipid antigens, glycoarray was used to establish how the anti-
bodies bound to various lipids in complex with sulfatide. In general, the
antibodies fell into two broad categories, herein termed Groups A and
B. Group A (GAME-M5 and GAME-G3) bound to sulfatide and some
sulfatide complexes, but were unable to bind sulfatide when presented
with complex gangliosides (Fig. 2A). Group B antibodies bound all
sulfatide-associated complexes regardless of interaction with any other
lipids or glycolipids tested, including complex gangliosides (GAME-M2,
GAME-M6 and GAME-M7) (Fig. 2B). O4 was found to be most similar to
the group B antibodies as it bound to all sulfatide associated complexes
at this antibody concentration (Fig. 2C).
Serologically, CST−/− mice responded to sulfatide immunisation
similarly to CST+/+ mice. Interestingly, hybridoma screening revealed
the presence of IgG antibodies, which were not detected in mouse
serum. We therefore considered that any circulating anti-sulfatide an-
tibodies might be actively depleted from the circulation through a re-
ceptor-dependent endocytosis clearance mechanism, as previously ob-
served for anti-ganglioside antibodies (Cunningham et al., 2016). To
investigate this, CST+/+ and CST−/− mice were passively immunised
with 250 μg/ml of GAME-G3 and bled at days 1, 3, 6 and 7 to monitor
serum levels of anti-sulfatide antibodies (Fig. 2D). Both genotypes had
signiﬁcantly higher levels of anti-sulfatide antibodies on day 1 fol-
lowing passive delivery of GAME-G3 compared to baseline, as would be
expected, and were not signiﬁcantly diﬀerent to each other (two way
ANOVA, P < 0.05). Over the following days, there was no signiﬁcant
diﬀerence in antibody levels between the genotypes at any time-point.
This indicated that the antibodies were not being actively cleared from
the circulation through endocytosis in an antigen-dependent manner.
Fig. 1. Mice produce anti-sulfatide antibodies in response to immunisations with sulfatide containing liposomes. CST−/−(n=6), CST+/+ (n= 3) and DBA mice
(n=3) were immunised with liposomes comprised of sulfatide, SM, Chol and DCP. Combinatorial glycoarray blots from the terminal bleed sera and plots of the
single sulfatide reactivity (measured by ﬂuorescent intensity on array) in sera over time indicate the IgM and IgG antibody responses. (A) IgM antibodies against the
liposome components could be detected in sera from all genotypes, particularly against sulfatide and sulfatide-associated complexes. A representative blot from
CST−/− mouse sera is shown. (B) The levels of anti-sulfatide IgM reactivity rose with each consecutive immunisation but there was no signiﬁcant/measurable
diﬀerence between the CST−/− and CST+/+ sera at any time-point. In contrast, the level of anti-sulfatide antibodies in the DBA mice were signiﬁcantly higher than
the other genotypes on day 21 (two way ANOVA, P < 0.05). (C) IgG antibodies were detected against SM, Chol and associated complexes but negligible reactivity to
sulfatide was detected. A representative blot from CST−/− mouse sera is shown. (D) Anti-sulfatide IgG antibodies only appeared in the DBA sera on Day 28. There
was no detectable anti-sulfatide IgG antibodies in the sera of either the CST−/− or CST+/+ mice. Array areas spotted with vehicle only are marked with an X. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 1
Binding speciﬁcity of anti-sulfatide antibodies as determined by lipid micro-
array. The antibodies were screened at 10 μg/ml for IgM and 1 μg/ml for IgG on
lipid microarray. Values indicate the median ﬂuorescent intensity (MFI) of the
antibodies to sulfatide.
Group mAb Immunogen Genotype Isotype Sulfatide MFI
A GAME-M5 Sulfatide liposomes CST+/+ IgM 5279
A GAME-G3 Sulfatide liposomes CST+/+ IgG3 5029
B GAME-M2 Sulfatide liposomes CST+/+ IgM 43341
B GAME-M6 WLE liposomes CST+/+ IgM 22901
B GAME-M7 WLE liposomes CST+/+ IgM 9322
– O4 Homogenate of Bovine
White Matter
IgM 11325
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3.3. Anti-sulfatide antibody binding to biological membranes is determined
by physiological condition
Anti-sulfatide mAbs were next probed against cells and tissues to
determine if they were capable of binding to sulfatide as it is physio-
logically displayed in living biological membranes. Binding studies
were ﬁrst carried out by probing the antibodies against myelinating
CNS cultures, in which oligodendrocytes are known to express high
levels of sulfatide and bind O4 (Mirsky et al., 1990; Reynolds and
Hardy, 1997). Within both groups, mAbs demonstrated similar binding
patterns, one antibody from each group being illustrated (Fig. 3A).
Whilst all antibodies in Groups A and B bound to oligodendrocytes in
myelinating cultures, group B antibodies and O4 bound more strongly
than those in group A. Based upon the glycoarray screening it is thus
possible that sulfatide on oligodendrocyte membranes may cis-interact
in the plane of the plasma membrane with neighbouring gangliosides or
other glycolipids, thereby preventing access to the epitope on sulfatide
that Group A antibodies target. Such an interaction would result in
attenuated binding.
Subsequently, the mAbs were probed against peripheral nerve
transverse sections from both CST+/+ and CST−/− mice to determine
how they interacted with sulfatide in mature myelinated peripheral
nerve tissue (Fig. 3B). All the antibodies bound strongly to the trans-
verse nerve bundles in the CST+/+ tissue, whereas no binding was
detected in the CST−/− tissue, conﬁrming that the antibodies were
speciﬁcally binding to sulfatide. Binding encircled the axonal neuroﬁ-
lament staining in a halo pattern, suggesting labelling of the sulfatide-
enriched myelin. Additional extra-myelinic staining of structures was
present with the O4 mAb, albeit weakly in the CST−/− tissue, sug-
gesting non-speciﬁc binding. To determine whether the mAbs were able
to bind physiologically intact living nerve membranes, we ﬁrst used live
ex vivo triangularis sterni (TS) nerve muscle preparations that contain
distal myelinated motor nerve ﬁbres (Fig. 3C). Both group A and group
B mAbs bound along the myelin internode and strongly at the para-
nodal loops of the terminal heminode. In comparative contrast, binding
with O4 was weaker, patchy in distribution, or undetectable, despite
having a similar binding proﬁle to Group B antibodies. Binding of all
mAbs was most prominent distally, due to available access to this site
and did not advance further proximally, presumably due to limitation
on access aﬀorded by the blood-nerve barrier (BNB).
3.4. Anti-sulfatide antibody binding to mouse peripheral nerve following
passive immunisation in vivo
The ability of the anti-sulfatide antibodies to speciﬁcally bind sul-
fatide-containing neural membranes in vivo was assessed by passively
immunising CST+/+ and CST−/−mice with the anti-sulfatide IgG mAb,
GAME-G3 (1mg total dose per mouse, delivered IP). When in-
tramuscular nerve ﬁbres were examined for the presence of mAb de-
posits, prominent binding was observed in paranodal regions and at the
terminal hemi-node. In contrast to the situation in transverse frozen
sections, where internodal myelin staining was prominent, internodal
myelin was weakly labelled compared with paranodal Schwann cell
membranes. Figs. 4A & B demonstrate prominent GAME-G3 binding at
paranodal loops (asterisks) and weaker staining along the internodal
myelin in small intramuscular peripheral nerve bundles from CST+/+
mice. As expected, CST−/− mice demonstrated no binding. When ex-
amining more proximal sites such as the sciatic nerve and spinal roots
we detected no antibody binding (Fig. 4B), after up to 5 days of ex-
posure in vivo. To assess the functional capacity of bound antibody, we
exposed mouse distal nerves to GAME-G3 and a source of human
complement in a live ex vivo nerve-muscle preparation as above and
probed the tissue for evidence of complement activation. GAME-G3
bound to the distal nerves and activated the complement cascade,
culminating in the deposition of membrane attack complex (MAC)
pores at distal myelin and nodes of Ranvier (Fig. 4C).
4. Discussion
Monoclonal antibodies (mAbs) of known antigen speciﬁcity and
tissue binding capability are an invaluable resource to study antigen
localisation and function, and the immunopathogenesis of autoanti-
body-mediated autoimmune disease. A particular feature of anti-gly-
colipid mAbs is the diversity of binding patterns exhibited by antibodies
Fig. 2. Monoclonal anti-sulfatide antibodies bind to sulfatide and associated complexes on lipid microarray. Newly generated monoclonal anti-sulfatide antibodies
were screened against sulfatide antigen printed on a lipid microarray. The IgM antibodies were screened at 10 μg/ml and the IgG antibodies were screened at 1 μg/ml.
Their binding patterns fell into two broad categories. (A) Group A comprises GAME-M5 and GAME-G3 antibodies that bind exclusively to sulfatide and sulfatide
complexes that do not contain complex gangliosides at the concentrations used. (B) Group B comprises GAME-M2, GAME-M6 and GAME-M7 antibodies that bind
strongly to sulfatide and are not aﬀected by associated complexes. (C) O4 was screened for comparison purposes, and showed binding to sulfatide and associated
complexes in a similar pattern as the Group B antibodies. (D) CST−/− (n= 6) and CST+/+ (n= 6) mice were passively immunised with 250 μg of GAME-G3
antibody. Anti-sulfatide antibody levels were signiﬁcantly higher following immunisation on day 1 compared to day −1 (baseline) for both genotypes. Clearance
from the circulation does not diﬀer between the two genotypes, implying that clearance is not due to receptor-dependent uptake as has been seen for antibodies
against gangliosides. Results represent two independent experiments each with 3 mice per group. * Signiﬁcance at day 1 versus day−1, two-way ANOVA with Sidak's
multiple comparison test, p < 0.05. Array areas spotted with vehicle only are marked with an X.
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to a single glycan epitope, according to the topographical orientation of
the glycan in the plane of the plasma membrane. This diversity con-
founds antigen localisation studies, which for sulfatide are historically
mostly deﬁned by the bindings patterns of the O4 mAb (Sommer and
Schachner, 1981). Diﬀerential binding of diﬀerent anti-sulfatide anti-
bodies to sulfatide-containing membrane domains will also aﬀect both
the vulnerability of tissues to immune-mediated attack and the patho-
genicity of the antibodies that arise in various neuropathies. These
immunopathological features will not be deducible from interrogating
solid phase immunoassays such as ELISA or glycoarray in which pur-
iﬁed antigens are adhered to artiﬁcial surfaces prior to probing with
antibody. For sulfatide and other glycolipids, the antibody-binding
epitopes may be obscured or exposed depending upon the local mi-
croenvironment (Galban-Horcajo et al., 2014; Greenshields et al., 2009;
Nobile-Orazio et al., 2014). Studying these subtle nuances in the con-
text of sulfatide would greatly beneﬁt from the development of a
greater selection of monoclonal antibodies for neuropathy pathogenesis
studies than O4 provides. Understanding the characteristics of these
varied binding patterns will also allow us to determine the patterns of
sulfatide reactivity that are found in human neuropathy and other sera,
and thereby improve the screening conditions for identifying im-
munopathologically relevant human antibodies.
The mAb O4 is most commonly used to study and localise sulfatide.
Whilst O4 exposure has been shown to produce demyelination of CNS
tissue both in vitro and in vivo (Rosenbluth and Moon, 2003; Rosenbluth
et al., 2003), its use in studying sulfatide mediated peripheral nerve
pathology has proven diﬃcult. In our previous studies, we have been
unable to demonstrate anatomically interpretable and speciﬁc binding
of O4 to live peripheral nerve preparations, despite it being similar to
Group B antibodies. The explanation for this at the structural level is
unknown. As sulfatide is known to be expressed in peripheral nerve
myelin membranes, the absence of binding suggests that O4 is unable to
access the sulfatide epitope in Schwann cell membranes. Thus it may
not represent the heterogeneity of the anti-sulfatide antibody popula-
tions that arise in humans with either CNS or PNS demyelinating dis-
eases, or in immunised animals (Brennan et al., 2011).
We sought to address this by generating and characterising a larger
series of anti-sulfatide mAbs. This was achieved by B-cell cloning from
CST−/−, CST+/+ and DBA mice immunised with sulfatide and WLE
liposomes. DBA mice produced higher levels of anti-sulfatide antibodies
compared with CST+/+ and CST −/− mice the latter being a C57BL/6J
background. Previous success in using complex ganglioside deﬁcient
mice to generate anti-ganglioside antibodies (Bowes et al., 2002; Lunn
et al., 2000) led us to select the sulfatide deﬁcient CST−/− mouse for
immunisations. We expected that these mice would be immunologically
naïve, due to a lack of exposure to endogenous sulfatide, and would
therefore form a more robust immune response compared to sulfatide-
replete wild type mice. However, CST−/− mice did not produce anti-
sulfatide antibodies in greater amounts than their wild type counter-
parts, indicating that antigen naïvety does not play an obvious role in
regulating immune tolerance to sulfatide. The role of sulfatide-re-
stricted NK T cell activation by exogenous sulfatide administration was
not explored but is a possible confounding factor (Rhost et al., 2014).
The panel of anti-sulfatide mAbs were shown by combinatorial
glycoarray to have two binding patterns and were also distinct in some
binding capacities from the prototypic O4 mAb. The combinatorial
element of the glycoarray permitted the examination of how hetero-
meric complexes of lipids aﬀected antibody binding that can then be
compared with binding patterns in physiologically intact membranes.
In the presence of gangliosides as heteromeric partners, Group A mAbs
bound to sulfatide less well than Group B mAbs in solid-phase assays.
This lower binding signal was also reﬂected in the CNS cultures. As
certain gangliosides, particularly GD3 (Reynolds and Wilkin, 1988), are
enriched in these myelinating cultures, it is possible that the epitope of
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sulfatide favoured by Group A antibodies is not optimally exposed,
limiting the binding ability of these antibodies. This same inhibition,
however, was not observed in peripheral nerve sections or ex vivo
preparations, suggesting that sulfatide was presented diﬀerently in
these tissues.
Whilst we conﬁrmed that O4 mAb also bound sulfatide in solid-
phase arrays, myelinating culture and peripheral nerve sections, the
pattern was much more diﬀuse compared to the GAME mAbs that lo-
calised quite precisely to myelin and paranodal membranes. In parti-
cular, O4 mAb was rarely detected along the myelin in the distal motor
nerve of ex vivo preparations, in striking contrast to the GAME mAbs.
This suggests that the newly generated anti-sulfatide GAME series an-
tibodies bind to slightly diﬀerent epitope conﬁgurations or density ar-
rangements compared with O4 mAb, despite O4 mAb being a Group B
antibody. Antibody binding along distal nerves was very strong 24 h
after in vivo delivery into CST+/+ mice and not CST−/− demonstrating
the speciﬁcity of the antibody to sulfatide. Binding was observed on the
distal nerves of the diaphragm and lumbrical muscles, suggesting the
antibody was capable of entering the systemic circulation. However, the
antibody appeared to be occluded from trunk nerves, likely owing to
the protection aﬀorded by the BNB. It is possible that higher doses or
manipulation of the BNB permeability could allow access of antibody
and will be worth further investigation.
An important feature of the GAME anti-sulfatide mAbs was their
ability to activate the complement cascade at the distal motor nerve.
Whether this produced a pathological lesion in the myelin and Schwann
cell membranes remains to be determined in further studies. Although
O4 is also capable of activating complement, its inability to bind this
peripheral site gives the GAME antibodies an advantage in studying
murine models of human disease, as demyelination of the nerve is ob-
served with certain anti-sulfatide antibody-associated neuropathies and
demyelination has been associated with complement activity
(Rosenbluth and Moon, 2003; Storch and Lassmann, 1997). Comple-
ment may not be the only eﬀector of myelin disruption in demyeli-
nating diseases (Genain et al., 1999) and other complement-in-
dependent injury routes for these antibodies should be included in
future characterisations.
Due to the discrepancies in antibody presence between results from
serology and high-throughput screening of hybridoma supernatant, we
also investigated whether anti-sulfatide antibodies were removed from
the circulation via endocytic uptake, using GAME-G3 as a re-
presentative antibody. In contrast to a previous study using anti-gang-
lioside antibodies (Cunningham et al., 2016), comparisons of CST−/−
and CST+/+ indicated that the antibodies were not removed from the
circulation by sulfatide-mediated endocytosis. Despite the mechanism
of antibody clearance remaining unknown, the discrepancy between
detectable levels of IgG in the serum and in hybridoma supernatant
highlights the importance that serum levels of antibody do not re-
present the repertoire of antibodies being produced (Cunningham et al.,
2016).
In conclusion, we have generated and performed preliminary
characterisation of a series of new anti-sulfatide antibodies and de-
monstrated that they have a range of binding patterns that are distinct
from those of the most commonly studied anti-sulfatide antibody, O4.
By studying a more diverse range of antibodies, we will build upon the
existing knowledge of binding behaviours, which will ultimately aid us
in modelling and understanding their roles in autoimmune neuro-
pathies.
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